SCHEMBL10071826

SCHEMBL10071826

Cc1cc2c(cn1)cc(-c1cc(NC(=O)c3cc(OC4CCN(C)CC4)cc(C(F)(F)F)c3)ccc1C)c(=O)n2-c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 6/20 0.53
▸ KDR P35968 6/20 0.53
▸ SRC P12931 4/20 0.53
▸ INSR P06213 3/20 0.53
▸ LYN P07948 3/20 0.53
▸ HCK P08631 2/20 0.53
▸ CSF1R P07333 3/20 0.53
▸ SYK P43405 2/20 0.47
▸ MAPK14 Q16539 3/20 0.42
▸ ABL1 P00519 2/20 0.42
▸ BRAF P15056 7/20 0.42
▸ RAF1 P04049 6/20 0.42
▸ TYK2 P29597 1/20 0.41
▸ JAK3 P52333 1/20 0.41
▸ BTK Q06187 1/20 0.41
▸ PDGFRB P09619 1/20 0.40
▸ KIT P10721 1/20 0.40
▸ DDR1 Q08345 1/20 0.40
▸ TNK2 Q07912 1/20 0.39
▸ MAP4K2 Q12851 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043716 0.91 CSF1R (0.57) LCKKDRSRCINSRLYN
SCHEMBL502120 0.87 LYN (0.52) LCKKDRSRCINSRLYN
SCHEMBL10071745 0.84 CSF1R (0.52) LCKKDRSRCINSRLYN
SCHEMBL10043776 0.82 SYK (0.65) LCKKDRSYKMAPK14ABL1
SCHEMBL13437981 0.82 SYK (0.46) LCKKDRSRCINSRLYN
SCHEMBL10071825 0.81 SYK (0.45) LCKKDRSRCINSRLYN
SCHEMBL10072194 0.81 BRAF (0.51) LCKKDRSRCINSRLYN
SCHEMBL13376457 0.80 NR2E1 (0.55) LCKSRCLYNHCKCSF1R
SCHEMBL10071818 0.77 SYK (0.45) LCKKDRSRCINSRLYN
SCHEMBL10072021 0.77 SYK (0.59) LCKKDRSYKMAPK14ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 — — US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 — — US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 — — US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 — — US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC LCK 4/4885KDR 108/4885SRC 3/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC LCK 4/4885KDR 108/4885SRC 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback